Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia: Progress in a New Cancer Subtype

Julia Wells, PhD, Nitin Jain, MD, and Marina Konopleva, MD, PhD

Dr Wells is a postdoctoral fellow, Dr Jain is an assistant professor, and Dr Konopleva is a professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas.

Corresponding author:
Marina Konopleva, MD, PhD
Department of Leukemia
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Houston, TX 77030
E-mail: mkonople@mdanderson.org
Tel: (713) 794-1628
Fax: (713) 794-4297

Abstract: Philadelphia chromosome–like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile similar to that of Ph-positive ALL; however, the BCR-ABL1 fusion is not present. The World Health Organization classification of myeloid neoplasms and acute leukemia recently was updated to include the Ph-like or BCR-ABL1–like ALL subtype of B-cell ALL as a provisional entity. Unlike Ph-positive ALL, which is characterized by the pathognomonic BCR-ABL1 fusion, Ph-like ALL is characterized by a multitude of different genetic rearrangements and mutations. In this review, we outline the age-related and geographic incidence of Ph-like ALL, the association with worse clinical outcomes, and early evidence for the use of ruxolitinib (a Janus kinase 2 inhibitor) and dasatinib (a tyrosine kinase inhibitor targeting ABL1).

Introduction

The discovery, refinement, and specific characterization of cancer subtypes form the basis of precision medicine. Molecular characterization of cancer can be helpful for patients by detecting biomarkers for diagnosis or prognosis, or eligibility for reduced or targeted therapies. Increased individualized care through molecular classification has not come without obstacles, however. Problems occur with repeatability, predicting response to currently available treatments, identifying markers of metastasis, and identification of tumor targets for effective directed therapies. These shortcomings are unsurprising, given that subtle changes in the expression of just a few genes can produce a considerable number of downstream effects, which vary considerably from patient to patient and across the course of a disease. In addition, consensus is hampered by differences in study designs, sample sets, data processing, and algorithms. Overlap among studies has been achieved, however, through the use of large collaborations.

Leukemia was among the earliest of cancers to employ stratification of patients by risk of relapse in order to determine chemotherapy treatment intensity. Molecular subtyping in leukemia was introduced in the 1970s with the use of T-cell membrane markers for diagnosis.

Keywords
Acute lymphoblastic leukemia, BCR-ABL1–like, CRLF2, JAK2, Philadelphia chromosome–like
to determine prognosis. Further advances in molecular classification using chromosome number analysis found the minute chromosome 22, named the Philadelphia classification using chromosome number analysis found and chromosomal rearrangements in ALL.14,15 A recently techniques have identified new deletions, mutations, fication of available targeted therapies. These sequencing earlier diagnosis, a more accurate prognosis, and identi- subtyping, holding out promise in disease prevention,encing have advanced clinically meaningful molecular lymphoblastic leukemia (B-ALL).

Gene expression profiling and next-generation sequ- encing have advanced clinically meaningful molecular subtyping, holding out promise in disease prevention, earlier diagnosis, a more accurate prognosis, and identi- fication of available targeted therapies. These sequencing techniques have identified new deletions, mutations, and chromosomal rearrangements in ALL.14,15 A recently described subtype that has been added to the World Health Organization’s classification of myeloid neoplasms and acute leukemia is Philadelphia chromosome (Ph)-like ALL.16 Ph-like ALL is a new B-ALL subtype that is defined by a high expression of tyrosine kinase and cytokine receptor signaling genes and an expression profile similar to that of Ph-positive ALL, but without the BCR-ABL1 chromosomal rearrangement.17-19

**Diagnosing Ph-Like ALL**

Ph-like ALL was first described in children with B-ALL. The Dutch Childhood Oncology Group identified a probe set, corresponding to 110 genes, produced by hier- archical clustering of known subtypes. In the patients with so-called “B-other” ALL, consisting of those without identifiable cytogenetic features, many clustered with BCR-ABL1-positive cases and were considered to have BCR-ABL1–like ALL.17 St Jude Children’s Research Hospital and the Children’s Oncology Group (COG) identified a probe set, corresponding to 257 genes, that identified high-risk BCR-ABL1–positive patients using the prediction analysis for microarrays (PAM) method. They found that the IKAROS zinc finger 1 (IKZF1) gene not only had significant prognostic influence, it also was present in cases without BCR-ABL1 translocations. The researchers referred to the patients identified by this probe set as having high-risk BCR-ABL1–negative ALL.18 A signature comparison study, using a cohort of newly diagnosed childhood B-ALL, found intersecting but not identical groups using these 2 independent gene expression classifiers.20 Both classifiers identified patients with poor outcomes and tyrosine kinase fusion genes. However, only 18% of patients identified as having Ph-like ALL overlapped in both probe sets. This is not unexpected given that there are only 9 overlapping probe sets between the 2 studies owing to different strategies, algorithms, and patient demographics.

TARGET (Therapeutically Applicable Research to Generate Effective Treatments) is a collaboration between COG and the National Institutes of Health (NIH). This initiative developed a 15-gene low-density array (LDA) gene expression card that can be used in the clinical diagnostic laboratory setting using quanti- tative reverse transcriptase polymerase chain reaction (qRT-PCR). The probe sets capture immunoglobulin J polypeptide (IG), spermatogenesis associated serine rich 2 like (SPATS2L), mucin 4 (MUC4), cytokine receptor-like factor 2 (CRLF2), carbonic anhydrase 6 (CA6), neurexin 3 (NRXN3), bone morphogenic protein receptor type 1B (BMPR1B), G protein-coupled receptor 110 (GPR110), chimerin 2 (CHN2), semaphorin 6A (SEMA6A), paraoxonase 2 (PON2), solute carrier family 2 member 5 (SLC2A5), S100 calcium binding protein Z (S100Z), tumor protein P53 inducible nuclear protein 1 (TP53INP1), and interferon induced transmembrane protein 1 (IFITM1) gene expression, and identifies more patients with CRLF2 lesions compared with the original microarray probe set.21 The LDA card includes probes for the most frequent tyrosine kinase genomic mutations in Ph-like ALL, and is intended for identifying patients who may respond to tyrosine kinase–targeted therapy.22 COG recently used this LDA card in a retrospective analysis, where it proved to be a robust indicator of Ph-like ALL.23 As a result, COG has implemented this card in its current clinical trial, AALL1131 (NCT02883049).

**Incidence and Prognostic Significance of Ph-Like ALL**

The incidence of Ph-like ALL differs by geographic location, age, and certain genetic disorders. In Europe, the probe set from the Dutch Childhood Oncology Group was used to identify Ph-like ALL in 13% of adults in the GMALL (German Multicenter Study Group for Adult ALL) cohort24 and 17% of adults in the HOVON (Dutch-Belgian Hemato-Oncologie voor Volwassenen Nederland) study group.25 Children enrolled in the German and Dutch trial groups had a 16% incidence of Ph-like ALL. Within that subgroup, 40% had IKZF1 deletions and 16% had high CRLF2 expression.26 A Japanese cohort found that 4.7% of B-ALL cases were Ph-like by PCR and 11% by global gene expression analysis using their own clustering algorithms.27 An Australia and New Zealand Children’s Haematology/Oncology Group cohort found an incidence of 10% Ph-like ALL using the LDA card probe set.28 In the United States, both adolescents and adults have an increased frequency
of Ph-like ALL vs other types of ALL. An analysis of multiple studies of childhood ALL found that Ph-like ALL accounted for 10% of children with standard-risk ALL, 13% of children with high-risk ALL, 21% of adolescents with ALL, and 27% of young adults with ALL using the PAM-derived probe set.29 Another multicohort study of adult B-ALL found that 27.9% of young adults (ages 21 to 39 years), 20.4% of adults (ages 40 to 59 years), and 24.0% of older adults (ages 60 to 86 years) had Ph-like B-ALL, with classification including the 15-gene LDA.22 In a smaller US study, 18% of adults older than 40 years with B-ALL were classified as having Ph-like disease.30

We previously published results on an adult B-ALL cohort from the MD Anderson Cancer Center (MDACC). We found that of 148 patients, 33.1% had Ph-like ALL.31 The higher rates of Ph-like ALL seen in these cohorts from the MD Anderson Cancer Center have an elevated risk of developing ALL, and one of the larger Hispanic population being treated probe set possibly capturing a wider patient subset—with the LDA array and the PAM-associated risk model for B-ALL in an Egyptian cohort of children (including CRLF2 deletion).22,39 In a smaller US study, 18% of adults older than 40 years with B-ALL were classified as having Ph-like disease.30

Regardless, inferior outcomes in patients with Ph-like ALL are seen in both children and adults. In adults, lower rates of continuous complete remission and overall survival were found in Ph-like ALL patients in both Europe and the United States compared with other B-ALL subtypes.22,31 In children, Ph-like ALL patient cohorts from Europe, Japan, Australia, New Zealand, and the United States had poor outcomes, with shorter time to relapse and worse overall survival compared with those in most other B-ALL subtypes.7,18,28,40 The exceptions were patients with Ph-positive and mixed lineage leukemia (MLL)-rearranged cytogenetics, who had similarly poor outcomes. Childhood Ph-like ALL also was associated with a minimal residual disease level of at least 0.01%.41 These inferior outcomes have been the main impetus for the expanding studies of Ph-like ALL over the past decade, and for the continual efforts to refine the subtype and characterize it to advance therapeutic benefit.

**Molecular Characterization and Classification of Ph-Like ALL**

To match the correct patients with potential treatments, there was a need to further classify the Ph-like subtype. Patients were further distinguished by kinase or cytokine receptor genomic alterations that contribute to altered kinase signaling.29 This molecular classification covers more than 90% of reported cases. The remaining 4% to 10% of cases, depending on age, have no identifiable kinase-activating alteration.42

**Kinase Alterations**

The approval of imatinib for use in patients with BCR-ABL1–positive leukemia was followed by the approval of more effective second-generation tyrosine kinase inhibitors.43,44 Although clinical responses have been impressive with these agents, resistance-inducing mutations and toxic side effects still pose problems.45 In Ph-like ALL, common kinase fusions targetable by these ABL inhibitors include ABL1, ABL2, colony stimulating factor 1 receptor (CSF1R), platelet-derived growth factor receptor alfa (PDGFRa), and platelet-derived growth factor receptor beta (PDGFRb).28 Other kinase fusions not in the ABL class include diacylglycerol kinase eta (DGKH), fms-related tyrosine kinase 3 (FLT3), neurotrophic receptor tyrosine kinase 3 (NTRK3), protein tyrosine kinase 2 beta (PTK2B) and B-cell linker (BLNK), which transduces signals from the B-cell receptor and activates the RAS pathway via ERK and casitas B-lineage lymphoma (CBL), a negative regulator of signal transduction pathways.22,29

**Cytokine Receptor Alterations**

Cytokine receptor fusions signal through the JAK/signal transducers and activators of transcription (STAT) pathway. This comprises the membrane-bound thymic stromal lymphopoietin receptor (TSLPR)/CRLF2, which
is functional when the CRLF2 subunit heterodimerizes with the interleukin 7 receptor alfa (IL7RA) subunit. Activation of the TSLPR by TSLP phosphorylates JAKs, which in turn activate various STATs. TSLP stimulation activates AKT serine/threonine kinase 1 (AKT1), extracellular signal–regulated kinase 1/2 (ERK1/2), Jun N-terminal kinases (JNKs), ribosomal protein S6 (RPS6), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1). Other CRLF2-positive ALL pathways include the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. Cytokine receptor–associated alterations that are targetable by JAK2 inhibitors include CRLF2 (approximately 50%-60% of adult Ph-like ALL cases), JAK2, and erythropoietin receptor (EPOR) gene rearrangements, all of which lead to increased JAK/STAT signaling.

Patients with CRLF2 alterations do particularly poorly. A COG study on childhood ALL found that high CRLF2 expression in high-risk ALL patients was associated with worse survival. The overwhelming majority of patients with CRLF2 overexpression have been associated with relapse and poor outcome in non–Ph-positive patients. Even moderate expression of CRLF2 as detected by flow cytometry has been associated with an increase in phosphorylation of STAT5.

The overwhelming majority of patients with CRLF2 overexpression have 1 of 2 fusion genes: purinergic receptor P2Y, G-protein coupled, 8 (P2RY8)-CRLF2 and immunoglobulin heavy chain locus (IGH)-CRLF2. IGH-CRLF2 is more common than P2RY8-CRLF2 in adults, whereas both the P2RY8-CRLF2 and IGH-CRLF2 fusion are found equally in children. P2RY8-CRLF2 has been associated with worse overall survival, but when present as a minor subclone, the fusion was not shown to be responsible for relapse in patients.

Additional cytokine receptor–related genes involved in Ph-like ALL fusion include interleukin 2 receptor subunit beta (IL2RB) and tyrosine kinase 2 (TYK2). In an adult cohort, 45% of patients with CRLF2 overexpression also had a JAK2 mutation. Gain of function mutations in CRLF2 also have been reported in adults, and to a lesser extent in children, who harbor a concomitant CRLF2 fusion. Additional mutations have been found in JAK1, JAK3, IL7R, and SH2B adaptor protein 3 (SH2B3).

CRLF2 alterations and JAK mutations are highly correlated with the presence of IKZF1 alterations, a zinc finger transcription factor required for normal lymphoid development. It is unclear from previous studies whether the presence of IKZF1 alterations leads to worse outcomes across all B-ALL subtypes. There is definitely a correlation between increased IKZF1 alterations and higher rates of relapse, including increased minimal residual disease in the Ph-like subtype, but whether IKZF1 has a causative role remains unknown.

Down syndrome is a genetic disorder involving trisomy of chromosome 21. It has been associated with an increased risk of B-ALL, including an increased risk of Ph-like ALL. In the retrospective Ponte Di Legno study covering 16 international trials, CRLF2 and JAK2 mutations were found to be common in people with Down syndrome and ALL. The P2RY8-CRLF2 fusion accounted for more than 90% of observed CRLF2 rearrangements owing to deletion of the pseudoautosomal region 1 of chromosomes X and Y. Among patients with Down syndrome, those who had CRLF2 gene rearrangements were younger than those with wild-type CRLF2. This age difference was not seen in patients without Down syndrome who had CRLF2 rearrangements. A previous study had also identified P2RY8-CRLF2 fusions in 53% of patients with Down syndrome–associated ALL vs 7% of those with ALL that was not associated with Down syndrome. The risk of ALL relapse was higher in patients with Down syndrome in the study. This was largely attributed to treatment-related mortality, however, and CRLF2 gene rearrangements did not have a significant association with any survival or relapse outcomes. This is in contrast to studies of patients with ALL that is not associated with Down syndrome.

Beyond kinase and cytokine receptor alterations, a subset of patients with RAS mutations also have Ph-like ALL. These patients may have mutations in KRA5, NRAS, neurofibromin 1 (NF1), protein tyrosine phosphatase, non-receptor type 11 (PTPN11), and BRAF. Novel fusions continue to emerge from the literature. An example is a LDLRAD4-PHACTR3 fusion—involving low-density lipoprotein receptor class A domain containing 4 (LDLRAD4) encoding a negative regulator of transforming growth factor beta (TGF-β) protein signaling and phosphatase and actin regulator 3 (PHACTR3). Also a paired box 5 (PAX5) rearrangement with kinase D-interacting substrate of 220 kDa (KIDINS220).

Tyrosine Kinase Inhibitors and Other Targeted Therapies

The first drugs to be tested for Ph-like ALL were tyrosine kinase inhibitors targeting SRC/ABL. Clinical evidence of targeted therapy response in case studies of patients with Ph-like ALL and preclinical studies led to phase 2 and 3 clinical trials using dasatinib (Sprycel, Bristol-Myers Squibb) and the JAK2 inhibitor ruxolitinib (Jakafi, Incyte Corporation).

Imatinib is a first-generation ABL kinase inhibitor that binds to the active and inactive conformations of the ABL kinase domain. In contrast, dasatinib is a second-generation ABL kinase inhibitor that binds the inactive and
active conformation of the ABL kinase domain with greater affinity and fewer contact points.

In one case, dasatinib combined with chemotherapy produced complete and ongoing remission in a child with Ph-like ALL who had an activating transcription factor 7 interacting protein (ATF7IP)-PDGFRB translocation.66 Two case studies both with young patients harboring an EBF1-PDGFRB fusion showed complete remission after treatment with imatinib in combination with conventional chemotherapy.67,68 In another case, an older patient with Ph-like ALL who had an ETV6-ABL1 rearrangement had an initial response to dasatinib, followed by a relapse with an ABL1 T315I mutation (this was previously discovered as a resistance mutation in patients with BCR-ABL1-positive disease).69 In another case, an adolescent patient with Ph-like ALL who had an RCSD1-ABL1 translocation was treated with the third-generation tyrosine kinase inhibitor ponatinib (Iclusig, Ariad). Ponatinib was selected through drug response profiling ex vivo and in patient-derived xenograft models, and the patient achieved clinical remission before relapsing after a hematopoietic stem cell transplant.70 In a final case, another adolescent with Ph-like ALL who had a JAK2 mutation was given combined chemotherapy with ruxolitinib, a JAK2 inhibitor that was previously approved for polycythemia vera and myelofibrosis, and achieved negative minimal residual disease before hematopoietic stem cell transplant and long-term remission.71 Ruxolitinib in this case was delivered at 40 mg/m² per day, given twice a day for 2 weeks on and 2 weeks off. The agent was introduced during the interim maintenance phase of high-dose conventional chemotherapy.

Based on these early successes, current clinical trials are identifying Ph-like ALL genetic lesions known to confer susceptibility to either ruxolitinib or dasatinib or by CRLF2 positivity by flow cytometry (for the ruxolitinib cohort). Two current clinical trials are assessing the effectiveness of ruxolitinib: a 2-armed MDACC trial of chemotherapy in combination with either ruxolitinib or dasatinib in patients aged 10 years and older who have Ph-like ALL,72 and a COG study of ruxolitinib plus chemotherapy in children aged 1 to 21 years who have Ph-like ALL (AALL 1521).73

Other active trials in Ph-like ALL include 2 trials from the National Cancer Institute. In the first trial, patients from age 1 to 30 years with newly diagnosed high-risk B-ALL and tyrosine kinase inhibitor–sensitive Ph-like mutations are receiving dasatinib and combination chemotherapy (COG AALL1131).74 In the second trial, adults aged 65 or older with dasatinib-sensitive mutations or kinase fusions involving ABL1, ABL2, CSF1R, PDGFRB, PDGFRα, and fibroblast growth factor receptor (FGFR) are receiving dasatinib.75

In the preclinical setting, there are still new drugs and strategies being tested for targeted Ph-like therapy (Table).

Preclinically, both ruxolitinib and the mTOR inhibitor rapamycin were found to be effective single agents against CRLF2 rearrangements with JAK2 mutations, and against 1 JAK1 mutation without a CRLF2 rearrangement. This supports the idea that JAK-mutated Ph-like ALL may act through the same JAK/STAT pathways regardless of CRLF2 status.76 However, other studies have shown in vitro that ruxolitinib, while inhibiting STAT5 phosphorylation, can leave mutated JAK2 in a constitutively active state of hyperphosphorylation.77 CHZ868 was developed as an improved, type 2 JAK kinase inhibitor that can better target JAK2 and bind the inactive state. CHZ868 has shown in vitro and in vivo success in models that proved refractory to ruxolitinib, and was proven to completely downregulate phosphorylation of JAK2 and STAT5 and downstream c-MYC, with a marked improvement in both potency and selectivity over other JAK2 inhibitors.78 This breakthrough will hopefully lead to clinical compounds with similar properties.

Gedatolisib, a dual PI3K/mTOR inhibitor, showed efficacy in vivo in mice engrafted with both CRLF2 and ABL-like fusions, as a single agent and in combination with ruxolitinib or dasatinib.79 Another Ph-like ALL study targeting multiple pathways found synergy of a MEK inhibitor, selumetinib, and a JAK2 inhibitor, AZD1480, in vitro. This synergy did not translate to the patient-derived xenograft setting, however, because the sustained target inhibition required was not achievable in vivo using tolerable drug dosing.80

More recent targets that can suppress the JAK/STAT pathway downstream of CRLF2 include an inhibitor of heat shock protein 90 (HSP90) called luminespib (previously NVP-AUY922). Luminespib leads to the degradation of JAK2, and can more potently suppress JAK/STAT, MAP kinase, and AKT signaling than the type 1 JAK2 inhibitor BV808. Luminespib was used in vivo on CRLF2-expressing patient-derived xenografts and showed modest prolonged survival.77,81 Birinapant, a second mitochondrial-derived activator of caspases (SMAC) mimic that can induce apoptosis by inhibiting the activity of cellular inhibitor of apoptosis protein 1/2 (cIAP1/2), has shown anti-leukemic activity in B-ALL PDX models both as a single agent and in combination with chemotherapy. The most acute sensitivity to birinapant was seen in the Ph-like ALL subtype, and was dependent on tumor necrosis factor α (TNF-α) expression.82

Another potential therapy targeting CRLF2 expression is epigenetic inhibitors. JQ1, an inhibitor of the bromodomain and extraterminal (BET) family of bromodomain proteins, was found to downregulate...
transcription of interleukin 7 receptor (IL7R), a heterodimer of CRLF2, and reduce JAK2 and STAT5 phosphorylation. JQ1 was an effective agent against a P2RY8-CRLF2–rearranged Ph-like ALL in vivo. Another epigenetic targeted drug, the histone deacetylase (HDAC) inhibitor givinostat, was used in a CRLF2-rearranged leukemia, with or without JAK2 mutations, and was found to effectively reduce STAT5 phosphorylation and reduce leukemia burden in vivo. New therapies that are highly specific to CRLF2 expression have also been developed. These include a CRLF2 antibody–armored biodegradable nanoparticle designed to deliver a drug payload. Another development is an immune strategy that uses an adoptive transfer of T cells that have been genetically modified to express the anti-TSLPR chimeric antigen receptor. These new therapeutic strategies may prove to have better efficacy than the tyrosine kinase inhibitors that have already moved to clinical trials in Ph-like ALL. However, further validation of their safety, specificity, and activity is needed.

Table. Current Investigated Therapies for Ph-Like Leukemia

<table>
<thead>
<tr>
<th>Drug (Developer)</th>
<th>Ph-Like ALL Target</th>
<th>Method of Action</th>
<th>Preclinical Studies</th>
<th>Clinical Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dasatinib (Bristol-Myers Squibb)</td>
<td>SRC/ABL class tyrosine kinase fusions</td>
<td>Type 2 SRC/ABL class tyrosine kinase inhibitor</td>
<td></td>
<td>Phase 2 and 3 clinical trials in progress (NCT02420717, NCT02883049, and NCT02143414)</td>
</tr>
<tr>
<td>Ponatinib (Ariad)</td>
<td>SRC/ABL class tyrosine kinase fusions</td>
<td>Type 3 SRC/ABL class tyrosine kinase inhibitor</td>
<td></td>
<td>Single case study</td>
</tr>
<tr>
<td>Givinostat (Italfarmaco)</td>
<td>CRLF2+</td>
<td>Class 1 and class 2 HDAC inhibitor</td>
<td>In vitro and in vivo studies</td>
<td></td>
</tr>
<tr>
<td>JQ1 (Roche)</td>
<td>CRLF2+</td>
<td>BET inhibitor</td>
<td>In vitro and in vivo studies</td>
<td></td>
</tr>
<tr>
<td>Luminespib (Novartis)</td>
<td>CRLF2+</td>
<td>HSP90 inhibitor</td>
<td>In vitro and in vivo studies</td>
<td></td>
</tr>
<tr>
<td>Selumetinib (Astra-Zeneca) and AZD1480 (InvivoGen)</td>
<td>CRLF2+</td>
<td>MEK 1/2 inhibitor and ATP-competitive JAK2 inhibitor</td>
<td>In vitro studies</td>
<td></td>
</tr>
<tr>
<td>TSLPR CAR T cells (National Cancer Institute)</td>
<td>CRLF2+</td>
<td>Allogeneic TSLPR CAR T cells</td>
<td>In vitro and in vivo studies</td>
<td></td>
</tr>
<tr>
<td>Ruxolitinib (Incyte)</td>
<td>JAK2-mutated</td>
<td>Type I JAK2 inhibitor</td>
<td>In vitro and in vivo studies (not for clinical use)</td>
<td></td>
</tr>
<tr>
<td>CHZ868 (Novartis)</td>
<td>JAK2-mutated</td>
<td>Type 2 JAK2 inhibitor</td>
<td>In vitro and in vivo studies</td>
<td>Phase 2 clinical trials in progress (NCT02420717 and NCT02723994)</td>
</tr>
<tr>
<td>Rapamycin (Pfizer)</td>
<td>mTOR-activated pathways</td>
<td>Inhibitor of mTOR</td>
<td>In vitro and in vivo studies</td>
<td></td>
</tr>
<tr>
<td>Gedatolisib (Pfizer)</td>
<td>PI3K and mTOR-activated pathways</td>
<td>Dual inhibitor of PI3K-α, PI3K-γ and mTOR</td>
<td>In vitro and in vivo studies</td>
<td></td>
</tr>
<tr>
<td>Birinapant (TetraLogic)</td>
<td>TNF-α-dependent</td>
<td>SMAC mimetic</td>
<td>In vitro and in vivo studies</td>
<td></td>
</tr>
</tbody>
</table>

ABL, Abelson murine leukemia viral oncogene homolog; ALL, acute lymphoblastic leukemia; BET, bromodomain and extraterminal; CAR, chimeric antigen receptor; CRLF2+, cytokine receptor-like factor 2–positive; HDAC, histone deacetylase; JAK2, Janus kinase 2; mTOR, mammalian target of rapamycin; Ph-like, Philadelphia chromosome–like; PI3K, phosphoinositide 3-kinase; SMAC, second mitochondria-derived activator of caspases; TNF-α, tumor necrosis factor alpha; TSLPR, thymic stromal lymphopoietin receptor.
Conclusions

Ph-like ALL is a high-risk subgroup of B-ALL that is seen in approximately 20% to 30% of adolescents and adults with B-ALL. With the use of chemotherapy, outcomes of patients of all ages with Ph-like ALL are significantly inferior to those of patients without the Ph-like gene expression signature. JAK inhibitors and ABL kinase inhibitors are being investigated in clinical trials in patients with Ph-like ALL. The addition of Ph-like ALL to the already known cytogenetic subgroups of ALL is another step toward personalized medicine in the context of treatment of B-ALL.

Disclosures

Drs Jain and Konopleva have received research support from Incyte.

References


